StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) bonds

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Aclaris Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Aclaris Therapeutics's 10-K for the period ended Oct 31, 2018

Aclaris Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Term Loan Facility$65.00M

See a number that looks wrong?